Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141). Issue 10 (24th June 2020)

• Record Type: Journal Article
• Authors: Yen, Chia‐Jui; Kiyota, Naomi; Hanai, Nobuhiro; Takahashi, Shunji; Yokota, Tomoya; Iwae, Shigemichi; Shimizu, Yasushi; Hong, Ruey‐Long; Goto, Masahiro; Kang, Jin‐Hyoung; Li, Wing Sum Kenneth; Ferris, Robert L.; Gillison, Maura; Endo, Toshimitsu; Jayaprakash, Vijayvel; Tahara, Makoto
• Is Part Of: Head & neck. Volume 42:Issue 10(2020)
• Page Start: 2852
• Page End: 2862
• Publication Date: 2020-06-24
• Subjects: Asian population -- clinical trial -- immunotherapy -- nivolumab -- squamous cell carcinoma of the head and neck; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.26331
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: The present study evaluated the 2‐year survival of the Asian population in the CheckMate 141 trial. Methods: The CheckMate 141 trial included patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). In the present study, 34 Asian patients (nivolumab group: 23 patients; investigator's choice of therapy [IC] group: 11 patients) were analyzed. Results: The median overall survival (OS) was 12.1 and 6.2 months for the nivolumab and IC groups, respectively. The estimated 2‐year OS rates were 22.7% and 0% for the nivolumab and IC groups, respectively. In the nivolumab group, the patients with any treatment‐related adverse events (TRAEs), including skin‐related disorders, showed better OS than the patients without any TRAEs. Conclusions: Nivolumab demonstrated prolonged OS benefits in the Asian population with platinum‐refractory R/M SCCHN and a favorable safety profile. TRAEs, including skin‐related disorders, may be favorable prognostic factors for nivolumab efficacy. Clinical trial registration: NCT02105636.